Go Pro
OTCMKTS:INBP

Integrated BioPharma Q4 2025 Earnings Report

Integrated BioPharma logo
$0.18 +0.02 (+12.69%)
As of 02:56 PM Eastern

Integrated BioPharma EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Integrated BioPharma Revenue Results

Actual Revenue
$14.18 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Integrated BioPharma Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Integrated BioPharma Earnings Headlines

The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
Integrated BioPharma Holds 2025 Annual Stockholder Meeting
INBP Integrated BioPharma, Inc.
See More Integrated BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Integrated BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Integrated BioPharma and other key companies, straight to your email.

About Integrated BioPharma

Integrated BioPharma (OTCMKTS:INBP), Inc. is a health and wellness company focused on the development, manufacturing and distribution of nutritional supplements, vitamins, herbal products and related consumer health offerings. The company serves businesses and consumers seeking products in the dietary supplement and natural health categories.

Its activities have included contract manufacturing and private-label production, as well as the sale and distribution of finished nutritional and wellness products. These capabilities may include formulation, manufacturing, packaging and related services for supplement companies and other customers.

Integrated BioPharma has historically operated in the United States and has served customers through domestic and international distribution channels. Publicly available information about its current operating structure, principal brands and leadership is limited, so additional details cannot be stated reliably.

View Integrated BioPharma Profile